

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated Wednesday, January 27, 2021 (the “**Prospectus**”) issued by Suzhou Basecare Medical Corporation Limited (the “**Company**”).

This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). This announcement is for information purposes only and does not constitute an invitation or offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering before deciding whether or not to invest in the Offer Shares.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”). The securities may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.



Suzhou Basecare Medical Corporation Limited
蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2170)

**PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION,
STABILIZING ACTIONS AND END OF STABILIZATION PERIOD**

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-Allotment Option described in the Prospectus has been partially exercised by the Joint Global Coordinators on behalf of the International Underwriters on March 3, 2021 in respect of an aggregate of 6,859,000 H Shares (the “**Over-allotment Shares**”), representing approximately 10.29% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option. The Over-allotment Shares will be issued and allotted by the Company at HK\$27.36 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Share under the Global Offering.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on Wednesday, March 3, 2021, being the 30th day after the last day for lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by the Stabilizing Manager, or any person acting for it during the stabilization period are set out in this announcement.

PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The Company announces that the Over-Allotment Option described in the Prospectus has been partially exercised by the Joint Global Coordinators on behalf of the International Underwriters on March 3, 2021 in respect of 6,859,000 H Shares, representing approximately 10.29% of the Offer Shares initially available under the Global Offering before any exercise of the Over-Allotment Option. The Over-allotment Shares will be issued and allotted by the Company at HK\$27.36 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%), being the Offer Price per Offer Share under the Global Offering.

APPROVAL OF LISTING

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee. Listing of and dealing in the Over-allotment Shares are expected to commence on the Main Board of the Stock Exchange at 9:00 a.m. on March 8, 2021.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON THE PARTIAL EXERCISE OF THE OVER-ALLOTMENT OPTION

The shareholding structure of the Company immediately before and immediately after the completion of the partial exercise of the Over-Allotment Option is as follows:

Description of Shares	Immediately before the completion of partial exercise of the Over-allotment Option		Immediately after the completion of partial exercise of the Over-allotment Option	
	Number of issued Shares	Approximate % of issued share capital	Number of issued Shares	Approximate % of issued share capital
Domestic Shares	183,181,817	68.69%	183,181,817	66.97%
Unlisted Foreign Shares	9,410,765	3.53%	9,410,765	3.44%
H Shares converted from Unlisted Foreign Shares	7,407,418	2.78%	7,407,418	2.71%
H Shares issued under the Global Offering	66,667,000	25.00%	73,526,000	26.88%
Total	266,667,000	100%	273,526,000	100%

USE OF PROCEEDS

The Company will receive the net proceeds of approximately HK\$182 million (after deducting the underwriting commissions and other estimated expenses in connection with the exercise of the Over-Allotment Option) for the 6,859,000 H Shares to be issued and allotted following the partial exercise of the Over-Allotment Option and will use the net proceeds for the purposes as set out in the section headed “Future Plans and Use of Proceeds” in the Prospectus.

STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company further announces that the stabilization period in connection with the Global Offering ended on Wednesday, March 3, 2021, being the 30th day after the last day for lodging of applications under the Hong Kong Public Offering. The stabilizing actions undertaken by the Stabilizing Manager, or any person acting for it during the stabilization period are set out below:

- (a) over-allocation of an aggregate of 10,000,000 H Shares in the International Offering, representing 15% of the total number of Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option;
- (b) successive purchases of an aggregate of 3,141,000 H Shares in the price range of HK\$24.70 to HK\$27.35 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period. The last purchase made by the Stabilizing Manager on the market during the stabilization period was on March 3, 2021 at the price of HK\$27.35 per H Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%); and
- (c) the partial exercise of the Over-allotment Option by the Joint Global Coordinators on behalf of the International Underwriters on March 3, 2021 in respect of an aggregate of 6,859,000 H Shares, representing approximately 10.29% of the total number of the Offer Shares initially available under the Global Offering before any exercise of the Over-allotment Option, at the Offer Price per Offer Share to facilitate the delivery to cornerstone investors who have agreed to delayed delivery of H Shares subscribed by them under their respective cornerstone investment agreements.

The portion of the Over-allotment Option which has not been exercised by the Joint Global Coordinators on behalf of the International Underwriters lapsed on March 3, 2021.

PUBLIC FLOAT

Immediately after the end of the stabilization period and after the partial exercise of the Over-allotment Option, the Company will continue to comply with the public float requirements under Rule 8.08(1)(a) and Rule 18A.07 of the Listing Rules.

By Order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Hong Kong, March 3, 2021

As of the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Mr. RUI Maoshe as executive Directors, Mr. XU Wenbo, Mr. ZHANG Jiecheng and Mr. WANG Weipeng as non-executive Directors, and Dr. KANG Xixiong, Dr. HUANG Taosheng and Mr. YU Kwok Kuen Harry as independent non-executive Directors.